[68Ga]Ga-PSMA-11与[18F]FDG PET/CT在多发性骨髓瘤中的头对头比较
本研究对20例症状性、活检证实的多发性骨髓瘤患者行全身[18F]FDG与[68Ga]Ga-PSMA-11 PET/CT,两次检查间隔1-8天。共检出266个病灶,[18F]FDG检出223/266(84%)个、[68Ga]Ga-PSMA-11检出190/266(71%)个,仅一种示踪剂显示的病灶占近一半,提示两者可能互补。
要点
- [18F]FDG检出223/266(84%)个病灶,[68Ga]Ga-PSMA-11检出190/266(71%)个病灶。
- 仅[68Ga]Ga-PSMA-11检出43个(16%)病灶,仅[18F]FDG检出76个(29%)病灶,两者共同检出147个(55%)。
- 两种示踪剂在病灶数量、软组织病灶数量及最高SUVmax上的一致性良好(ICC≥0.75)。
核心结论
- [18F]FDG或[68Ga]Ga-PSMA-11单用均可检出大多数多发性骨髓瘤病灶,近一半病灶仅摄取其中一种示踪剂,提示两者可能具有互补作用。
- 部分病例[68Ga]Ga-PSMA-11摄取明显,提示在特定患者中可能采用诊疗一体化方法。
研究设计与样本
- 前瞻性纳入20例症状性、活检证实的多发性骨髓瘤患者,行全身[18F]FDG与[68Ga]Ga-PSMA-11 PET/CT,两次检查间隔1-8天。
- 对所有病灶计数并测量最大SUV(SUVmax),采用组内相关系数(ICC)评估两种检查的一致性。
主要发现
- 19/20例患者共检出266个病灶;[18F]FDG在17例患者中检出223/266(84%)个病灶,[68Ga]Ga-PSMA-11在19例患者中检出190/266(71%)个病灶。
- 1例患者两种检查均未发现活动性病灶;仅[68Ga]Ga-PSMA-11检出43个(16%)病灶,仅[18F]FDG检出76个(29%)病灶,两者共同检出147个(55%)病灶。
- 147个共同检出病灶中25个存在FDG-PSMA摄取不匹配,见于8例不同患者;4例患者同一体内存在仅摄取[18F]FDG或仅摄取[68Ga]Ga-PSMA-11的不同病灶。
- [18F]FDG与[68Ga]Ga-PSMA-11最高SUVmax的中位数(最小值-最大值)分别为6.5(2.0-37.8)和5.5(1.7-51.3)。
- [18F]FDG和[68Ga]Ga-PSMA-11分别检出18个和19个软组织病灶;[18F]FDG假阳性病灶对[68Ga]Ga-PSMA-11的摄取极低或无摄取。
关键数值与推荐
- 病灶数量、软组织病灶数量及每例患者最高SUVmax的ICC≥0.75,一致性良好。
临床怎么用
- 作者认为[18F]FDG或[68Ga]Ga-PSMA-11单用均可检出大多数多发性骨髓瘤病灶,两者可能具有互补作用。
- 作者认为部分病例[68Ga]Ga-PSMA-11摄取明显,提示在特定患者中可能采用诊疗一体化方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to compare [18F]FDG and [68Ga]Ga-PSMA-11 PET/CT image findings in patients with multiple myeloma (MM). METHODS: Twenty consecutive patients with symptomatic biopsy-proven MM were submitted to whole body [18F]FDG and [68Ga]Ga-PSMA-11 PET/CT with a time interval of 1-8 days between procedures. All lesions were counted and had their maximum SUV (SUVmax) measured. Intra-class correlation (ICC) was used to assess the agreement between [18F]FDG and [68Ga]Ga-PSMA-11 PET/CT findings. RESULTS: A total of 266 lesions were detected in 19/20 patients. [18F]FDG detected 223/266 (84%) lesions in 17 patients and [68Ga]Ga-PSMA-11 190/266 (71%) lesions in 19 patients. Both procedures did not identify any active lesion in 1 patient. Forty-three (16%) lesions were detected only by [68Ga]Ga-PSMA-11 and 76 (29%) only by [18F]FDG. Both tracers identified 147 (55%) lesions. Intralesional mismatch of FDG-PSMA uptake was identified in 25 of these 147 lesions, found in 8 different patients. Different lesions with uptake of only [18F]FDG or [68Ga]Ga-PSMA-11 in the same patient were found in 4 patients. The highest SUVmax of [18F]FDG and [68Ga]Ga-PSMA-11 had a median (min-max) SUVmax of 6.5 (2.0-37.8) and 5.5 (1.7-51.3), respectively. [18F]FDG and [68Ga]Ga-PSMA-11 respectively identified 18 and 19 soft tissue lesions. False-positive [18F]FDG findings had minimal or no uptake of [68Ga]Ga-PSMA-11. Good reliability (ICC ≥ 0.75) was found for number of lesions, number of soft tissue lesions and highest SUVmax in each patient. CONCLUSION: [18F]FDG or [68Ga]Ga-PSMA-11 alone can detect most MM lesions. Almost half of the lesions take up only one of the tracers, reflecting increased glycolysis or angiogenesis in specific lesions, and suggesting their possible complementary role in MM. The marked [68Ga]Ga-PSMA-11 uptake in some cases raises the possibility of a theranostic approach in selected patients.
引用
- Souza SPM, Frasson FC, Takahashi MES, et al. Head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]FDG PET/CT in multiple myeloma. Eur J Nucl Med Mol Imaging. 2023. PMID: 36988710. doi:10.1007/s00259-023-06214-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。